Fab-based bispecific antibody formats with robust biophysical properties and biological activity

A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism

(2015) Zhi Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improving target cell specificity using a novel monovalent bispecific IgG design

(2015) Yariv Mazor et al.   mAbs

Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies

(2015) Xiufeng Wu et al.   mAbs

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

(2014) Steven M Lewis et al.   NATURE BIOTECHNOLOGY

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8

(2014) Irene Michalk et al.   PLoS One

Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

(2014) Jens A. A. Fischer et al.   Arthritis & Rheumatology

Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore

(2013) Eric S. Day et al.   ANALYTICAL BIOCHEMISTRY

Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization

(2013) B. Li et al.   CANCER RESEARCH

Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule

(2013) Clarissa G. Jakob et al.   mAbs

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody

(2013) Lei Wang et al.   PLoS One

Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2

(2013) Christian Jost et al.   STRUCTURE

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

(2013) Hannah Byrne et al.   TRENDS IN BIOTECHNOLOGY

The structural basis of αβ T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function

(2012) Jia-huai Wang et al.   IMMUNOLOGICAL REVIEWS

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators

(2012) Justin M. Scheer et al.   PLoS One

Bispecific antibodies engage T cells for antitumor immunotherapy

(2011) Bryan D Choi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging antibody combinations in oncology

(2011) Stephen J. Demarest et al.   mAbs

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

(2010) Jianying Dong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators

(2009) Nazzareno Dimasi et al.   JOURNAL OF MOLECULAR BIOLOGY

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH